Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101

doi:10.1016/0090-1229(88)90074-8

Clinical Immunology and Immunopathology

Volume 47, Issue 2, May 1988, Pages 219-229

Clinical Immunology ...

https://doi.org/10.1016/0090-1229(88)90074-8 Get rights and content

Abstract

We have previously demonstrated that the murine monoclonal antibody T101 induces antigenic modulation when infused into patients with chronic lymphocytic leukemia and cutaneous T-cell lymphoma. In this paper, we extend our studies of T101-induced modulation and compare it to T101-induced capping. We found that, in contrast to antigenic modulation, capping occurred only in the presence of secondary anti-mouse IgG antisera and was altered by drugs that affect the cellular cytoskeleton or energy metabolism. F(ab′)₂ fragments of T101 induced antigenic modulation with kinetics similar to those of intact T101, but Fab-induced modulation proceeded more slowly and required the continual presence of Fab throughout the incubation. Experiments with radioiodinated T101 demonstrated that initial internalization of the antibody is followed by rapid efflux of intact, immunoreactive T101 from the cells. These data indicate important differences between capping and modulation and suggest that these two phenomena proceed by different mechanisms. More importantly, the data have implications for the potential therapeutic use of monoclonal antibody immunoconjugates.

References (36)

R.O. Dillman et al.
Blood
(1982)
K.A. Foon et al.
Blood
(1984)
D.L. Shawler et al.
Clin. Immunol. Immunopathol.
(1986)
P. Parham et al.
J. Immunol. Methods
(1982)
E. Lamoyi et al.
J. Immunol. Methods
(1983)
F. Loor et al.
Exp. Cell Res.
(1980)
E.A. Boyse et al.
J. Natl. Cancer Inst.
(1963)
L.J. Old et al.
J. Exp. Med.
(1968)
L. Chatenoud et al.
Eur. J. Immunol
(1982)
D.L. Shawler et al.
Cancer Res.
(1984)

R.W. Schroff et al.

J. Immunol

(1984)

G. Schreiner et al.

Adv. Immunol.

(1976)

D.B. Drachman et al.

C.W. Stackpole et al.

Nature (London)

(1974)

R.O. Dillman et al.

J. Clin. Oncol.

(1984)

R.O. Dillman et al.

J. Biol. Resp. Mod.

(1986)

R.K. Oldham et al.

J. Clin. Oncol.

(1984)

F.G. Sears et al.

J. Biol. Resp. Mod.

(1984)

Cited by (16)

Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies
2024, Transplantation and Cellular Therapy
Chimeric antigen receptor T cell (CAR-T) immunotherapy has revolutionized the treatment of relapsed and refractory B cell-derived hematologic malignancies. Currently, there are 6 Food and Drug Administration-approved commercial CAR-T products that target antigens exclusively expressed on malignant B cells or plasma cells. However, concurrent advancement for patients with rarer and more aggressive T cell-derived hematologic malignancies have not yet been achieved. CAR-T immunotherapies are uniquely limited by challenges related to CAR-T product manufacturing and intrinsic tumor biology. In this review tailored for practicing clinician-scientists, we discuss the major barriers of CAR-T implementation against T cell-derived neoplasms and highlight specific scientific advancements poised to circumvent these obstacles. We summarize salient early-stage clinical trials implementing novel CAR-T immunotherapies specifically for patients with relapsed and/or refractory T cell neoplasms. Finally, we highlight novel manufacturing and treatment strategies that are poised to have a meaningful future clinical impact.
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
2015, Blood
Citation Excerpt :
However, surface expression of CD5 was comparable in all leukemic cell lines and activated T cells (supplemental Figure 7A-B). Ligand binding induces rapid internalization of CD5 protein even without crosslinking.29,30 We assessed the kinetics of CD5 internalization in normal and malignant T cells after mixing them with CD5 CAR T cells.
Options for targeted therapy of T-cell malignancies remain scarce. Recent clinical trials demonstrated that chimeric antigen receptors (CARs) can effectively redirect T lymphocytes to eradicate lymphoid malignancies of B-cell origin. However, T-lineage neoplasms remain a more challenging task for CAR T cells due to shared expression of most targetable surface antigens between normal and malignant T cells, potentially leading to fratricide of CAR T cells or profound immunodeficiency. Here, we report that T cells transduced with a CAR targeting CD5, a common surface marker of normal and neoplastic T cells, undergo only limited fratricide and can be expanded long-term ex vivo. These CD5 CAR T cells effectively eliminate malignant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma lines in vitro and significantly inhibit disease progression in xenograft mouse models of T-ALL. These data support the therapeutic potential of CD5 CAR in patients with T-cell neoplasms.
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: Historical precedence and recent developments
2015, Blood
A specialized form of trogocytosis occurs when Fcγ receptors on acceptor cells take up and internalize donor cell-associated immune complexes composed of specific monoclonal antibodies (mAbs) bound to target antigens on donor cells. This trogocytosis reaction, an example of antigenic modulation, has been described in recent clinical correlative studies and in vitro investigations for several mAbs used in cancer immunotherapy, including rituximab and ofatumumab. We discuss the impact of Fcγ-receptor–mediated trogocytosis on the efficacy of cancer immunotherapy and other mAb-based therapies.
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
2010, Blood
Citation Excerpt :
Although our preclinical data with XmAb5574 show potential promise for clinical investigation in CLL, there are potential pitfalls to be considered as this therapeutic antibody moves forward to the clinic. XmAb5574 binds to CD19 but shows concentration- and time-dependent internalization similar to other CD19 and CD5 antibodies that have been described.46,47 Although our studies in Figure 1C show continued expression of CD19 on the external portion of the CLL cells, it is possible that the internalization observed with this antibody could compromise its efficacy compared with clinically used antibodies such as alemtuzumab and rituximab that internalize less.
CD19 is a B cell–specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies. XmAb5574 is a novel engineered anti-CD19 monoclonal antibody with a modified constant fragment (Fc)–domain designed to enhance binding of FcγRIIIa. Herein, we demonstrate that XmAb5574 mediates potent antibody-dependent cellular cytotoxicity (ADCC), modest direct cytotoxicity, and antibody-dependent cellular phagocytosis but not complement-mediated cytotoxicity against CLL cells. Interestingly, XmAb5574 mediates significantly higher ADCC compared with both the humanized anti-CD19 nonengineered antibody it is derived from and also rituximab, a therapeutic antibody widely used in the treatment of CLL. The XmAb5574-dependent ADCC is mediated by natural killer (NK) cells through a granzyme B–dependent mechanism. The NK cell–mediated cytolytic and secretory function with XmAb5574 compared with the nonengineered antibody is associated with enhanced NK-cell activation, interferon production, extracellular signal-regulated kinase phosphorylation downstream of Fcγ receptor, and no increased NK-cell apoptosis. Notably, enhanced NK cell–mediated ADCC with XmAb5574 was enhanced further by lenalidomide. These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19⁺ B-cell malignancies.
Antigen Loss From Antibody-Coated Red Blood Cells
2009, Transfusion Medicine Reviews
Citation Excerpt :
Antigen loss has also been seen in the setting of monoclonal antibody treatment of neoplasia. This was originally termed antigenic modulation and was observed by several groups using both primary lymphocytes and cell lines.44-48 A particularly detailed analysis of antigenic modulation has been performed by Taylor et al using a therapeutic anti-CD20 antibody (ie, rituximab) and its target (ie, neoplastic or primary B cells).
Clinically significant signs and symptoms of hemolysis can result from the transfusion of crossmatch incompatible blood, the development of anti–red blood cell (RBC) alloantibodies posttransfusion, or the development of autoantibodies to RBCs (ie, autoimmune hemolytic anemia). However, a less understood and poorly appreciated phenomenon is when an antibody induces the loss of its target antigen without significant damage to the cells themselves. This has been referred to as “depressed antigen,” “antigen suppression,” “weakened antigenicity,” and “antigen loss.” This phenomenon has been observed for multiple blood group antigens on human RBCs, in addition to antigens on leukocytes, platelets, neurons, and neoplastic cells. This review discusses the published human case reports of antigen loss in each of the contexts described above and describes several experimental models, including whole animal models and in vitro culture systems. Our current understanding of the cellular and molecular mechanisms is discussed, and the role of antigen loss phenomena in both normal immune function and in disease states is reviewed.
Anti-T cell immunotoxins: a look at post-endocytotic receptor-mediated routing
1993, Journal of Controlled Release
Many types of targeted drug delivery systems utilize cell surface receptor binding to achieve targeting specificity. Receptor-mediated endocytosis also provides internalization of the targeted drug. What has not been previously appreciated is the fact that cell surface receptors play an important post-endocytotic role. After endocytosis the receptor ligand interaction determines how the ligand-drug complex will be routed. In many cases this routing uniquely determines the overall efficacy of the drug delivery system. In this paper we will show that a unique anti-T cell immunotoxin, anti-CD3⁺-CRM9, constructed with a diphtheria toxin binding site mutant, CRM9, is a highly effective reagent for inducing in vivo T cell ablation. The high degree of efficacy and the wide therapeutic margin of this reagent is a consequence of the obligatory intracellular routing pathway required for diphtheria toxin (DT) intoxication. The DT receptor (DTR) typically fulfills this function in diphtheria toxin intoxication. In the case of the anti-CD3⁺ toxin conjugate the routing function is performed by CD3. This epitope routes parallel with DTR. This fact accounts for the high toxicity of anti-CD3 conjugates made with diphtheria toxin binding site mutants such as CRM9. CRM9 alone is incapable of entering the optimal routing pathway and hence has very low systemic toxicity. The anti-CD3 antibody doubly complements the CRM9 defect: It facilitates (1) the entrance of CRM9 into the targeted cell endosomes and (2) directs the entrance of CRM9 into the DT intoxication pathway. It is likely that these concepts will have relevance to other cell type-specific immunotoxins and other cell type-specific targeted delivery systems which depend on the membrane translocation of bio-active macromolecules into the cytosol or nuclear compartments.

View all citing articles on Scopus

View full text

Regular articleMechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101

Abstract

Blood

Blood

Clin. Immunol. Immunopathol.

J. Immunol. Methods

J. Immunol. Methods

Exp. Cell Res.

J. Natl. Cancer Inst.

J. Exp. Med.

Eur. J. Immunol

Cancer Res.

J. Immunol

Adv. Immunol.

Nature (London)

J. Clin. Oncol.

J. Biol. Resp. Mod.

J. Clin. Oncol.

J. Biol. Resp. Mod.

Regular article
Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101